Scholarlink

Objective <p>To examine the correlation between the therapeutic efficacy of sufentanil preconditioning on hepatic ischemia-reperfusion injury (HIRI)-induced ferroptosis and the activation of activating transcription factor 3 (ATF3), as well as to elucidate the underlying mechanisms involved.</p> Methods <p>Eighteen Sprague-Dawley (SD) male rats were randomly assigned to three groups: a sham operation group, an ischemia-reperfusion injury group, and a sufentanil pretreatment group. Serum transaminase levels, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were measured to assess liver function. Liver injury was evaluated using hematoxylin and eosin staining. Ferroptosis was assessed by measuring iron content, glutathione peroxidase 4 (GPX4) expression levels, and mitochondrial morphological changes in hepatocytes. The relationship between the protective effects of sufentanil and ATF3 was investigated through immunohistochemistry, Western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR).</p> Results <p>Sufentanil pretreatment was found to ameliorate liver tissue damage, attenuate the inflammatory response, and mitigate ferroptosis in the context of HIRI. Furthermore, Sufentanil enhanced the expression levels of ATF3 while concurrently reducing iron content within liver tissue.</p> Conclusion <p>Sufentanil preconditioning may mitigate ferroptosis associated with HIRI through the upregulation of ATF3 expression. This protective mechanism may be linked to a concomitant reduction in iron levels.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sufentanil preconditioning reduces hepatic ischemia-reperfusion injury in rats by regulating ferroptosis through ATF3

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月23日

查看全文
  • Zhi-Hao Feng,
  • Yun-Fei Bao,
  • Yan-Yan Niu,
  • Hai-Jie Liu,
  • Qing Hu,
  • Jian-Ling Li

摘要

Objective

To examine the correlation between the therapeutic efficacy of sufentanil preconditioning on hepatic ischemia-reperfusion injury (HIRI)-induced ferroptosis and the activation of activating transcription factor 3 (ATF3), as well as to elucidate the underlying mechanisms involved.

Methods

Eighteen Sprague-Dawley (SD) male rats were randomly assigned to three groups: a sham operation group, an ischemia-reperfusion injury group, and a sufentanil pretreatment group. Serum transaminase levels, specifically alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were measured to assess liver function. Liver injury was evaluated using hematoxylin and eosin staining. Ferroptosis was assessed by measuring iron content, glutathione peroxidase 4 (GPX4) expression levels, and mitochondrial morphological changes in hepatocytes. The relationship between the protective effects of sufentanil and ATF3 was investigated through immunohistochemistry, Western blotting, and quantitative real-time polymerase chain reaction (qRT-PCR).

Results

Sufentanil pretreatment was found to ameliorate liver tissue damage, attenuate the inflammatory response, and mitigate ferroptosis in the context of HIRI. Furthermore, Sufentanil enhanced the expression levels of ATF3 while concurrently reducing iron content within liver tissue.

Conclusion

Sufentanil preconditioning may mitigate ferroptosis associated with HIRI through the upregulation of ATF3 expression. This protective mechanism may be linked to a concomitant reduction in iron levels.